Cancer Letters · 2024 · 27 citations · 47 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyBladder CancerCancer ImmunotherapyCancer ProgressionImmune Checkpoint InhibitorsTumor Microenvironment ModulationTumor-associated MacrophagesM2 Macrophage PhenotypesM2-like Macrophage ActivationMetastatic Bladder CancerMetastatic Urothelial Carcinoma ImmunotherapyProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-1 InhibitionTumor-associated Macrophage PolarizationTumor-associated Macrophage Reprogramming
47
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman, Chih Long Liu, Michael R. Green et al. · Nature Methods · 2015 · 14.1K citations · Full text
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations
Life Sciences, Immunology, Oncology +16
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +17